Daniela Vilasboas-Campos

  • Brain disorders,
  • Single-cell transcriptomics
  • Reward and aversion circuits
  • drug screening
I am a Research Assistant at ICVS/School of Medicine, University of Minho, where I work on the ERC Consolidator Grant “Challenging Current Models of Valence Encoding in the Mammalian Brain”. My research focuses on how reward and aversion shape molecular, transcriptomic and circuit-level responses in nucleus accumbens circuits, integrating RNA sequencing with behavioural, optogenetic and circuit-level approaches, with relevance for addiction and neuropsychiatric disorders.
I completed my PhD in Biomedicine and Health Sciences in 2026, with a focus on translational neurodegeneration research. During my doctoral training, I developed a fast-throughput C. elegans phenotypic screening platform to identify compounds that enhance recovery from proteotoxic stress in vivo, and contributed to genetic and sequencing studies of patient cohorts aimed at identifying disease modifiers.
My scientific output includes first-author and collaborative peer-reviewed publications. I have presented my work in 40 poster presentations and 11 oral communications at national and international conferences/events. My work has been recognized with multiple competitive distinctions, including the Best Oral Communication Prize from the Portuguese Society for Movement Disorders and 8 individual travel grants awards. I have supervised medical students and mentored researchers, including Master’s students, PhD candidates and postdoctoral researchers. I have participated as teaching staff in advanced training courses in neuroscience and bioinformatics and am an active member of national and international scientific societies, including FENS, ESN, ISN and SPN. Additionally, I contribute to multiple research projects, including past and ongoing grants funded by the “la Caixa” Foundation, ERC, US Department of Defense, FCT, NAF, Ataxia UK and the BIAL Foundation.
Overall, my work bridges translational disease-oriented research and systems neuroscience, with the goal of identifying mechanistic targets for brain disorders.

Daniela Vilasboas-Campos

  • Brain disorders,
  • Single-cell transcriptomics
  • Reward and aversion circuits
  • drug screening
I am a Research Assistant at ICVS/School of Medicine, University of Minho, where I work on the ERC Consolidator Grant “Challenging Current Models of Valence Encoding in the Mammalian Brain”. My research focuses on how reward and aversion shape molecular, transcriptomic and circuit-level responses in nucleus accumbens circuits, integrating RNA sequencing with behavioural, optogenetic and circuit-level approaches, with relevance for addiction and neuropsychiatric disorders.
I completed my PhD in Biomedicine and Health Sciences in 2026, with a focus on translational neurodegeneration research. During my doctoral training, I developed a fast-throughput C. elegans phenotypic screening platform to identify compounds that enhance recovery from proteotoxic stress in vivo, and contributed to genetic and sequencing studies of patient cohorts aimed at identifying disease modifiers.
My scientific output includes first-author and collaborative peer-reviewed publications. I have presented my work in 40 poster presentations and 11 oral communications at national and international conferences/events. My work has been recognized with multiple competitive distinctions, including the Best Oral Communication Prize from the Portuguese Society for Movement Disorders and 8 individual travel grants awards. I have supervised medical students and mentored researchers, including Master’s students, PhD candidates and postdoctoral researchers. I have participated as teaching staff in advanced training courses in neuroscience and bioinformatics and am an active member of national and international scientific societies, including FENS, ESN, ISN and SPN. Additionally, I contribute to multiple research projects, including past and ongoing grants funded by the “la Caixa” Foundation, ERC, US Department of Defense, FCT, NAF, Ataxia UK and the BIAL Foundation.
Overall, my work bridges translational disease-oriented research and systems neuroscience, with the goal of identifying mechanistic targets for brain disorders.

Scientific Highlights

1 – D. Vilasboas-Campos, J. H. Fernandes, M. D. Costa, J. Pereira-Sousa, J. Lopes, L. Costa-Meireles, B. Ferreira-Lomba, J. D. Da Silva, P. Maciel, A. Teixeira-Castro, PRO-FitS: a novel phenotypic assay to identify enhancers of proteostasis in C. elegans. [Preprint] (2026). https://doi.org/10.64898/2026.01.22.701023 .
2 – A. Silva, S. Duarte‐Silva, P. M. Martins, B. Rodrigues, D. Serrenho, D. Vilasboas‐Campos, A. Teixeira‐Castro, J. Vieyto‐Nuñez, J. Mieres‐Perez, F. Figueiredo, M. Podlasiak, T. Van‐der‐Kellen, J. Fraga, J. Noble, C. Lantz, N. Sepanj, D. Monteiro‐Fernandes, S. Guerreiro, A. Neves‐Carvalho, J. Pereira‐Sousa, F. Klärner, T. Schrader, J. A. Loo, A. Pastore, E. Sanchez‐Garcia, G. Bitan, A. L. Carvalho, P. Maciel, S. Macedo‐Ribeiro, Allosteric Modulation of Pathological Ataxin‐3 Aggregation: A Path to Spinocerebellar Ataxia Type‐3 Therapies. Advanced Science, e02216 (2025). https://doi.org/10.1002/advs.202502216
3 – Duarte-Silva, S.*, Da Silva, J. D.*, Monteiro-Fernandes, D.*, Costa, M. D., Neves-Carvalho, A., Raposo, M., Soares-Cunha, C., Correia, J. S., Nogueira-Goncalves, G., Fernandes, H. S., Oliveira, S., Ferreira-Fernandes, A. R., Rodrigues, F., Pereira-Sousa, J., Vilasboas-Campos, D., Guerreiro, S., Campos, J., Meireles-Costa, L., Rodrigues, C. M. P., Cabantous, S., Sousa, S. F., Lima, M., Teixeira-Castro, A., & Maciel, P. (2024). Glucocorticoid receptor-dependent therapeutic efficacy of tauroursodeoxycholic acid in preclinical models of spinocerebellar ataxia type 3. The Journal of Clinical Investigation, 134(5), e162246. https://doi.org/10.1172/JCI162246
4 – L. Aguiar, L. Royon, R. Bastos-Gonçalves, T. Carvalho, E. Teixeira, A. Faria, A.V. Domingues, D. Vilasboas-Campos, R.M. Jungmann, N. Vasconcelos, L. Pinto, S. Fernandez, J. Barik, B. Coimbra, A. Rodrigues, Adaptive changes of cholinergic projections to the nucleus accumbens bidirectionally mediate cocaine reinforcing effects. [Preprint] (2025). https://doi.org/10.1101/2025.06.30.662309.
5 – R. Correia, A. V. Domingues, L. A. A. Aguiar, M. Cunha-Macedo, D. Vilasboas-Campos, N. Vieitas-Gaspar, R. M. Jungmann, E. Teixeira, B. Coimbra, A. J. Rodrigues, C. Soares-Cunha, Dissociable neuronal substrates for positive and negative valence stimuli in the nucleus accumbens. [Preprint] (2026). https://doi.org/10.64898/2026.01.24.701496.
6 – Raposo, M., Bettencourt, C., Melo, A. R. V., Ferreira, A. F., Alonso, I., Silva, P., Vasconcelos, J., Kay, T., Saraiva-Pereira, M. L., Costa, M. D., Vilasboas-Campos, D., Bettencourt, B. F., Bruges-Armas, J., Houlden, H., Heutink, P., Jardim, L. B., Sequeiros, J., Maciel, P., & Lima, M. (2022). Novel Machado-Joseph disease-modifying genes and pathways identified by whole-exome sequencing. Neurobiology of Disease, 162, 105578. https://doi.org/10.1016/j.nbd.2021.105578
7 – Costa, M. D., Da Silva, J. D., Almeida, D., Pereira-Sousa, J., Vilasboas-Campos, D., Fernandes, J. H., Teixeira-Castro, A., & Maciel, P. (2025). Differential effects of lifespan-extending genetic manipulations in an animal model of MJD/SCA3. Mechanisms of ageing and development, 225, 112064. https://doi.org/10.1016/j.mad.2025.112064
8 – Vilasboas-Campos, D., Costa, M. D., Teixeira-Castro, A., Rios, R., Silva, F. G., Bessa, C., Dias, A. C. P., & Maciel, P. (2021). Neurotherapeutic effect of Hyptis spp. leaf extracts in Caenorhabditis elegans models of tauopathy and polyglutamine disease: Role of the glutathione redox cycle. Free Radical Biology & Medicine, 162, 202–215. https://doi.org/10.1016/j.freeradbiomed.2020.10.018
9 – Vilasboas-Campos, D., Costa, M. D., Teixeira-Castro, A., Rios, R., Silva, F. G., Aierken, A., Zhang, X., Bessa, C., Dias, A. C. P., & Maciel, P. (2020). Data on the effects of Hyptis spp. and Lycium spp. plant extracts in C. elegans models of genetically determined neurodegenerative diseases. Data in Brief, 33, 106598. https://doi.org/10.1016/j.dib.2020.106598
10 – Figueiredo, F., Sárkány, Z., Silva, A., Vilasboas-Campos, D., Maciel, P., Teixeira-Castro, A., Martins, P. M., & Macedo-Ribeiro, S. (2023). Drug repurposing of dopaminergic drugs to inhibit ataxin-3 aggregation. Biomedicine & Pharmacotherapy, 165, 115258. https://doi.org/10.1016/j.biopha.2023.115258

 

Add Your Heading Text Here

Projects

As Leader

Projects

As Member

Serotonin signaling and proteostasis

This project addresses an unmet medical need- the lack of effective treatment for any of the aging-associated neurodegenerative diseases. Due to the worldwide aging of the population, by 2050 it is expected that over 135 million people…

Read More